C-reactive protein and platelet–lymphocyte ratio as diagnostic biomarkers for hepatitis C-related hepatocellular carcinoma
The Egyptian Journal of Haematology · 2026-01 · 51 (1) · 1-11
DOI: 10.4103/ejh.ejh_133_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Egyptian Journal of Haematology, online erschienen am 26.03.2026. Verfasst von Hala M. El Feky und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background Hepatocellular carcinoma (HCC), is the most common type of liver cancer. Recent studies have shown that alpha-fetoprotein (AFP) has poor sensitivity and specificity for precise monitoring and diagnosis. The purpose of this study was to check if C-reactive protein (CRP) and platelet–lymphocyte ratio (PLR) could be used as markers to detect HCC in Egyptian patients. Patients and methods Ninety adult cirrhotic patients were sequentially recruited for this cross-sectional investigation. Group I (HCC patients with AFP
Zitieren
APA
Feky, H. M. E., El-Ghaffar, A. O., Mostafa, A. A., Naeim, R. A., & El-Bahy, A. M. (2026). C-reactive protein and platelet–lymphocyte ratio as diagnostic biomarkers for hepatitis C-related hepatocellular carcinoma. The Egyptian Journal of Haematology, 51(1), 1-11. https://doi.org/10.4103/ejh.ejh_133_25
Vancouver
Feky HME, El-Ghaffar AO, Mostafa AA, Naeim RA, El-Bahy AM. C-reactive protein and platelet–lymphocyte ratio as diagnostic biomarkers for hepatitis C-related hepatocellular carcinoma. The Egyptian Journal of Haematology. 2026;51(1):1-11. doi:10.4103/ejh.ejh_133_25
BibTeX
@article{Feky2026,
author = {Feky, Hala M. El and El-Ghaffar, Amira O.A. and Mostafa, Asmaa A. and Naeim, Reda A. and El-Bahy, Abeer M.},
title = {C-reactive protein and platelet–lymphocyte ratio as diagnostic biomarkers for hepatitis C-related hepatocellular carcinoma},
journal = {The Egyptian Journal of Haematology},
year = {2026},
volume = {51},
number = {1},
pages = {1--11},
doi = {10.4103/ejh.ejh_133_25}
}
EUVIMED